Home > Rheumatology > EULAR 2022 > Spondyloarthropathies – Novel Developments > Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib

Presented By
Prof. Lars Erik Kristensen , Copenhagen University Hospital, Denmark
Conference
EULAR 2022
Doi
https://doi.org/10.55788/ebf2b4a6
Post-hoc trial data revealed that rates of major adverse cardiovascular events (MACE) and malignancies in patients with psoriatic arthritis (PsA) and psoriasis (PsO) receiving tofacitinib vary according to their baseline atherosclerotic cardiovascular (CV) risk. Patients with intermediate and high baseline risk were predisposed to a higher incidence of events. PsA and PsO are linked to an increased burden of CV and metabolic comorbidities, and an association between CV disease and future development of malignant tumours has been described [1-4]. Recent concerns about the cardiovascular safety associated with JAK inhibitors in patients with rheumatoid arthritis have arisen. To explore this issue further, Prof. Lars Erik Kristensen (Copenhagen University Hospital, Denmark) and his fellow researchers performed a post-hoc analysis regarding patients with PsA and PsO treated with tofacitinib [1]. The analysed data comprised 3 PsA and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on